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Abstract:
Objective Atrioventricular nodal reentry tachycardia (AVNRT) is the most 
common form of paroxysmal supraventricular tachycardia (PSVT). 
Increasing data have shown familial clustering and involvement of 
genetic factors in AVNRT, and no pathogenic genes related to AVNRT 
have been reported. 
Methods Whole-exome sequencing (WES) was performed in 82 patients 
with AVNRT and 100 controls. Reference target genes, genome-wide 
association analysis (GWAS), gene-based collapsing and pathway 
enrichment analysis were performed. Protein-protein interaction (PPI) 
network was then established, WES database in the UK Biobank and one 
only genetic study of AVNRT in Denmark were used for external data 
validation. 
Results Among 129 reference target genes, 126 mutations were 
identified in the cases (MAF<0.001). Gene-based collapsing analysis and 
pathway enrichment analysis revealed six functional pathways related to 
AVNRT as with neuronal system/neurotransmitter release cycles and ion 
channel/cardiac conduction among the top 30 enriched pathways, then 
36 candidate pathogenic genes were selected. By combining with PPI 
analysis, 10 candidate genes were identified, including RYR2, NOS1, 
SCN1A, CFTR, EPHB4, ROBO1, PRKAG2, MMP2, ASPH, and ABCC8. From 
the UK Biobank database, 18 genes from candidate genes including 
SCN1A, PRKAG2, NOS1, CFTR had mutations in arrhythmias, and the 
mutations in PIK3CB, GAD2 and HIP1R were in patients with PSVT. 
Moreover, one mutation of RYR2 (c.4652A>G, p.Asn1551Ser) in our 
study was also detected in the Danish study. Considering the gene 
functional roles and external data validation, the most likely candidate 
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genes were SCN1A, PRKAG2, RYR2, CFTR, NOS1, PIK3CB, GAD2 and 
HIP1R. 
Conclusion The preliminary results first revealed potential candidate 
genes such as SCN1A, PRKAG2, RYR2, CFTR, NOS1, PIK3CB, GAD2 and 
HIP1R, and the pathways mediated by these genes, including neuronal 
system/neurotransmitter release cycles or ion channels/cardiac 
conduction, might be involved in AVNRT.
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Abstract
Objective Atrioventricular nodal reentry tachycardia (AVNRT) is the most common 
form of paroxysmal supraventricular tachycardia (PSVT). Increasing data have shown 
familial clustering and involvement of genetic factors in AVNRT, and no pathogenic 
genes related to AVNRT have been reported.
Methods Whole-exome sequencing (WES) was performed in 82 patients with AVNRT 
and 100 controls. Reference target genes, genome-wide association analysis (GWAS), 
gene-based collapsing and pathway enrichment analysis were performed. Protein-protein 
interaction (PPI) network was then established, WES database in the UK Biobank and 
one only genetic study of AVNRT in Denmark were used for external data validation.
Results Among 129 reference target genes, 126 deleterious rare mutations in 48 genes 
were identified in the cases (MAF<0.001). Gene-based collapsing analysis and pathway 
enrichment analysis revealed six functional pathways related to AVNRT as with neuronal 
system/neurotransmitter release cycles and ion channel/cardiac conduction among the top 
30 enriched pathways, then 36 candidate pathogenic genes were selected. By combining 
with PPI analysis, 10 candidate genes were identified, including RYR2, NOS1, SCN1A, 
CFTR, EPHB4, ROBO1, PRKAG2, MMP2, ASPH, and ABCC8. From the UK Biobank 
database, 18 genes from candidate genes including SCN1A, PRKAG2, NOS1, CFTR had 
mutations in arrhythmias, and the mutations in PIK3CB, GAD2 and HIP1R were in 
patients with PSVT. Moreover, one mutation of RYR2 (c.4652A>G, p.Asn1551Ser) in 
our study was also detected in the Danish study. Considering the gene functional roles 
and external data validation, the most likely candidate genes were SCN1A, PRKAG2, 
RYR2, CFTR, NOS1, PIK3CB, GAD2 and HIP1R.
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Conclusion The preliminary results first revealed potential candidate genes such as 
SCN1A, PRKAG2, RYR2, CFTR, NOS1, PIK3CB, GAD2 and HIP1R, and the pathways 
mediated by these genes, including neuronal system/neurotransmitter release cycles or 
ion channels/cardiac conduction, might be involved in AVNRT.
Keywords: Atrioventricular nodal reentry tachycardia; whole-exome sequencing; 
Gene-based collapsing analysis; neurotransmitter release cycles pathway; ion channels 
related pathway; Ion channel genes.
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Introduction
Atrioventricular nodal reentrant tachycardia (AVNRT), caused by a reentry circuit 
involving fast and slow atrioventricular nodal pathways, is one of the most common types 
of paroxysmal supraventricular tachycardias (PSVTs) [1]. Although radiofrequency 
ablation has a satisfactory success rate in AVNRT, the precise anatomic structures that 
constitute the reentrant circuit are unresolved, and the specific pathogenesis has remained 
the subject of study over several decades [2, 3]. Because most patients with AVNRT 
experience the onset of their symptoms in early adulthood and lack other structural heart 
disease, AVNRT was once considered a congenital functional abnormality developed 
during cardiogenesis [4].
However, there are several reports of AVNRT occurring in twins and members of the 
same family [5-8], and first-degree relatives of patients with AVNRT present a hazard 
ratio of at least 3.6 for exhibiting AVNRT compared with the general population [8], 
indicating that genetic factors are involved in the etiology and mechanism of this disease. 
Familial Wolff-Parkinson-White syndrome, another type of PSVT, has been well 
recognized as a disease that is partly caused by gene mutations, and several responsible 
mutations in the PRKAG2 gene have been identified [9, 10]. However, much less is 
known about the potential hereditary contribution to AVNRT, and no related pathogenic 
genes have been reported to date.
Whole-exome sequencing (WES) is an efficient strategy for identifying pathogenic genes 
involved in complex Mendelian and/or non-Mendelian diseases. However, factors such as 
lack of large multiplex families, locus heterogeneity, and incomplete penetrance have 
hampered such efforts to identify pathogenic genes in many diseases. Recent advances in 
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gene-based collapsing analysis might overcome some of these limitations [11]. In 
addition, rather than investigating associations between single genetic variants and a 
phenotype, pathway analysis of WES data interrogates alterations in biological pathways 
and helps us identify the underlying genes that cause disease. Therefore, we hypothesize 
that the application of this more comprehensive approach may help elucidate the genetic 
etiology of AVNRT.
To our knowledge, there are no published studies examining rare coding variants across 
the genome in AVNRT. In the current pilot study, we examined AVNRT using WES to 
detect and identify possible disease-causing genes by gene-base burden, pathway 
enrichment and protein-protein interaction (PPI) analyses.
Subjects and Methods
The study participants were identified among patients treated with radiofrequency 
catheter ablation at the Department of Cardiology of the Sichuan Academy of Medical 
Sciences and the Sichuan Provincial People’s Hospital in the period from 2014 to 2017. 
A total of 100 unrelated ethnically matched healthy control subjects were recruited from 
the visitors to the Health Evaluation and Promotion Center of our hospital. Upon 
inclusion, blood sample tests, 12 lead electrocardiograms (ECGs), echocardiography and 
cardiac history were recorded. The control subjects were free of any cardiovascular 
diseases, arrhythmia, chronic anemia, diabetes mellitus, thyroid disorders, electrolyte 
disturbance, systemic immune diseases, malignant tumors or any other diseases known to 
cause arrhythmias. All subjects gave written informed consent for genetic screening. 
Ethical approval for this study was obtained from the ethics committee of the Sichuan 
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Academy of Medical Sciences and the Sichuan Provincial People’s Hospital.
Intracardiac Electrophysiological Study
Baseline intracardiac electrophysiological studies included atrial stimulation (burst or 
extra stimulus pacing) and ventricular stimulation in cases. AVNRT diagnosis was 
established according to published criteria and pacing maneuvers as applicable [12]. Dual 
atrial ventricular (AV) node physiology was defined as a ≥50 ms increment in the AH 
interval after a 10 ms decrement interval during single-atrial extra stimulation or a ≥50 
ms increment in the AH interval after shortening the pacing cycle length by 10 ms. If 
sustained AVNRT (lasting ≥30 s) was not induced, the same pacing maneuvers were 
repeated under isoproterenol infusion and withdrawal as previously described [13].
Next-generation DNA sequencing, Variant Calling and Annotation
DNA samples were extracted from peripheral blood using the QIAamp DNA Blood Mini 
and Maxi Kits (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. 
Entire exon sequences were enriched by using a SureSelect Human All Exon kit V6 
(Agilent Technologies, Santa Clara, CA, USA), and the libraries were sequenced on the 
Illumina HiSeq NovaSeq platform (Illumina, San Diego, CA, USA). The average read 
depth was 123, and on average, 96.4, 98.6 and 99.4% of exons were covered by at least 
20 reads, 10 reads and 4 reads, respectively (Supplement Figure-1 S15). Qualified 
sequence reads were aligned to the human reference genome (NCBI GRCh37) using the 
Burrows-Wheeler Aligner (BWA; version 0.5.17; http://bio-bwa. sourceforge. net/). 
SAMtools (version 0.1.18; http://samtools. sourceforge.net/), Picard (http://picard. 
sourceforge.net/) and GATK (http://www. broadinstitute.org/ gsa/wiki/index.php/ 
Home_Page) were used for removing duplicated reads, realignment, and recalibration. 
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Potential single nucleotide variants (SNVs) and small insertions and deletions were called 
and filtered by using GATK3.7. Then, high-confidence SNV and indel mutations were 
annotated using snpEff (Version 4.2; http://snpeff. sourceforge.net/). Furthermore, all 
variants were annotated according to the control population of the 1000 Genomes Project 
(2014 Oct release, http://www. 1000genomes. org), ExAC (http://exac.broadinstitute.org), 
EVS (http://evs.gs.washington. edu/EVS), and the disease databases of ClinVar 
(http://www. ncbi.nlm.nih. gov/clinvar) and OMIM (http://www.omim.org). Missense 
variants were evaluated as pathogenic variants when high damage effects were predicted 
by at least three out of five appropriate programs, including Sorting Intolerant from 
Tolerant [SIFT], Polyphen2-HDIV, MutationTaster and MutationAssessor.
Mutations in reference target genes
A total of 129 reference AVNRT target genes were selected to detect mutations in 
AVNRT cases and controls. The genes were selected based on the following criteria 
according to another pioneering study on gene mutations in AVNRT[14]: (1) PR 
interval-associated genes identified by genome-wide association studies [15], (2) genes 
selected based on cardiac expression levels [16], (3) plausible genes based on protein 
function and association with other arrhythmic diseases. Selected genes are listed in 
Supplementary Table S1.
Single-marker association analysis
We used GATK v3.7 CombineGVCFs to combine the whole-exome sequencing dataset 
with ethnically matched and unrelated subjects in the AVNRT cohort and the control 
group, followed by filtering with VQSR and PLINK1.9 (--geno 0.1 --hwe 0.0001) to 
obtain high-confidence variant datasets [17]. Furthermore, PLINK1.9 was applied to 
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check the multidimensional scaling (MDS) dataset based on raw Hamming distances for 
population stratification, identity by descent (IBD) calculation for sample pairs and 
Hardy-Weinberg equilibrium deviation for all markers. GWAS for the qualified 
high-confidence datasets was performed to compute the odds ratios (ORs) and p values in 
PLINK using Fisher’s exact test for dichotomous phenotypes (cases versus controls for 
AVNRT). Finally, we used a genome-wide threshold for significance of p <1 × 10−6. A 
quantile-quantile (Q-Q) plot was used to evaluate the resulting p values.
Gene-based collapsing analysis and pathway enrichment
We performed gene-based collapsing to combine the information on multiple deleterious 
rare variants into a single value per gene, with ethnically matched and unrelated subjects 
in the AVNRT cohort (n=82) and the control group (n=100). We defined deleterious rare 
mutations as nonsense, splice-site, indel and frameshift mutations. For statistical 
considerations, Fisher’s exact test methods were preferred to calculate the gene-based 
collapsing. Two groups with minor allele frequencies (MAFs) below 0.1% and 1% in the 
Exome Aggregation Consortium (ExAC) and 1000 Genomes Project databases were 
calculated separately. A p value < 0.05 was considered significant. The significant genes 
were submitted to the KOBAS3.0 web server (http://kobas.cbi.pku.edu.cn/kobas3) to 
obtain the functional gene set Reactome Pathway enrichment. Then, the rich factor was 
calculated, and the top 30 enriched pathways are shown based on the corrected p value.
Construction of the PPI network
The Search Tool for the Retrieval of Interacting Genes database (STRING) (Version 10.0, 
http://string-db.org) was used to predict the relationships among the screened genes and 
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identify the most relevant genes [18]. Based on experimental data, database entries, and 
coexpression, PPI node pairs with a score of combination >0.4 (medium confidence) 
were considered to be significant. Then, Cytoscape software (version 3.7.1) was used to 
visualize the resulting PPI network.
Results
Clinical data of the cases
Our analysis included WES data from 82 cases and 100 controls. All AVNRT patients 
were diagnosed by electrophysiologic examination and underwent radiofrequency 
ablation. Among the 82 cases included in our analyses, the mean age at symptom onset 
was 51.5±16.3 years old, and the ratio of females/males was 2.2:1. The median disease 
course was 4.0 years. Five patients had a history of syncope or approximate syncope, 3 
had a familiar history or suspected familiar history of AVNRT, and no patients exhibited 
any structural heart disease. In the electrophysiological study, 9 patients presented no 
jumping between dual AV nodes, isoproterenol infusion was used in 6 cases to induce the 
onset of AVNRT. Except for one patient who exhibited slow-slow and one with slow-fast, 
all other cases exhibited typical slow-fast AVNRT, and all cases were treated 
successfully with radiofrequency ablation, with only one case relapsing, more details see 
Supplementary Table S2. 
Referentially elated target gene mutations
Among the 129 reference target genes, 126 deleterious rare mutations in 48 genes were 
detected according to the definition of mutations with an MAF <0.001 in the ExAC and 
1000 Genomes Project databases: 11 mutations in KCNJ12 (n=11), 9 in RYR3 (n=9), 8 in 
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RYR2 (n=8), 7 in ZFHX3 (n=7), 6 in ANK2 (n=6); 5 in AKAP9 (n=5), SYNE2 (n=5), 
TRPM4 (n=5); 4 in CACNA1D (n=4), CACNA1I (n=4), GNB3 (n=5), MYH6 (n=4), 
SCN5A (n=4); 3 in HCN4 (n=3), KCNH2 (n=3), SCN1A (n=3), SCN3A (n=3); 2 in 
CACNA1G (n=2), CACNB2 (n=2), GJD3 (n=2), NUP155 (n=2), SCN4A (n=2), SCN10A 
(n=2), SYNP02L (n=2); 1 mutation in 1 case in following genes: ADRB2, C9orf3, CASQ2, 
CAV1, CAV3, ERG, HCN2, HCN3, ITPR1, KCNA4, KCNA5, KCND3, KCNN3, LMNA, 
PITX2, PKP2, PRKAG2, SCN1B, SCN4B, SCN9A, SLC8A1, SNTA1, SOX5 and TBX3 
(Supplementary Table S3, Figure 1). Among the above mutations in the listed genes, only 
2 controls exhibited 2 mutations in KCNJ12 and 1 mutation was found in one control 
subjed in each of HCN4, ANK2 and RYR2.
As PSVT has a prevalence of 22.5/10 000 persons and an incidence of 35/100 000 
person-years [19], and the sample examined in the current study was relatively small, we 
chose another definition of mutations with an MAF <0.01 in the ExAC and 1000 
Genomes Project databases, and a total of 227 mutations in 64 genes were detected. The 
details of the mutations are presented in Supplementary Table S4.
GWAS study for common variants
Single-nucleotide polymorphisms (SNPs) were removed from the pre-imputation dataset 
if they exhibited an MAF < 0.01 or a p value for Hardy-Weinberg equilibrium (HWE) < 
1×10−4 (Supplementary Figure 2). Association p values from the GWAS were reported in 
Q-Q plots and Manhattan plots (Figure 2, Supplementary Figure-2 S16). In the limited 
number of samples, SNPs with p values (Fish test) of less than less than 10-6 were shown 
in Supplementary Table S5.
Then, pathway enrichment was performed under the condition of including SNPs with 
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p<0.01 according to KEGG and Reactome databases. As shown in Figure 2, the 
following four related traits were among the top 30 pathways in the two databases: (1) 
vesicle-mediated transport; (2) axon guidance; (3) the Ca2+ signaling pathway; and (4) 
ion channel transport, and there were 20 genes in both the KEGG and Reactome database 
analyses, including ABLIM2, ASPH, ATP2B4, CACNA1G, DPYSL2, EPHA2, FES, 
MYL12A, NE01, PLXNA4, PLXNB1, PLXNC1, ROBO2, RYR1, RYR2, RYR3, SEMA5A, 
SEMA6D, SLIT3 and UNC5B (Table 1).
Gene-based collapsing analysis and pathway enrichment for rare variants
We carried out gene-based collapsing tests under 2 frequency categories (MAF <0.01 and 
MAF <0.001) with p values of less than 0.05 were included. The Q-Q plots, Manhattan 
figures and mutations of the genes were shown in Supplemental Figure-3 S17 and 
Supplemental Tables S6 and S7.
In pathway analysis, mutations are associated with genes, and genes are placed into sets. 
The pathway enrichment analysis was performed using the Reactome database, and there 
were 517 and 343 pathways enriched with an MAF<0.01 and MAF<0.001, respectively 
(Supplementary Tables S8, S9). Among the top 30 enriched pathways, there were 6 
related pathways (MAF <0.01) and 2 pathways related to AVNRT (MAF P<0.001) 
(Figure 3). In addition, 14 pathways other than the top 30 pathways exhibited potential 
functions associated with AVNRT with either an MAF <0.01 or MAF<0.001 (Table 2, 
3).
From the above related pathways, 36 candidate pathogenic genes were selected: ABCC8, 
AP1G2, ASPH, ATP2C2, BEGAIN, CD163, CFTR, COG4, COL5A1, COL4A3, CSF2RB, 
DOK4, EPHB4, EVL, GAD2, HEPH, HIPK2, HIP1R, KCNV2, LAMC1, LRFN4, MMP2, 
Page 12 of 46Clinical and Translational Medicine
For Review Only
12 / 28
NOS1, PIK3CB, PPFIA1, PRKAG2, PSMB11, ROBO1, SCN1A, SFTPA2, SLC9B1, 
SLC26A4, SLC12A4, SYT10, TCF7L1 and TSPOAP1 (Table 4). The mutant information 
for these candidate genes was listed in Supplemental Tables S10 and S11. Among the 
candidate genes, SCN1A and PRKAG2 were identified in arrhythmia diseases as reference 
target genes.
PPI network construction and analysis
To identify the most relevant genes among the above 36 candidate genes from 
gene-based collapsing analysis, the PPI network was constructed with STRING, which 
combined 64 reference target genes with mutations from the present study and 20 
selected genes among the top 30 enriched pathways according to both the KEGG and 
Reactome databases in a GWAS. The 9 most significant genes according to scores and 
nodes were NOS1 (score=6.795, nodes=8.5), SCN1A (score=6.071, nodes=10.5), CFTR 
(score=4.673, nodes=6.5), EPHB4 (score=4.483, nodes=7.5), PRKAG2 (score=4.335, 
nodes=8), ROBO1 (score=4.241, nodes=6.5), ASPH (score=3.001, nodes=3.5), MMP2 
(score=2.665, nodes=4) and ABCC8 (score=2.387, nodes=4.5). Remarkably, RYR2 
(score=14.88, nodes= 23.5) was ranked as the first PPI node among the reference target 
genes with mutations in the present study, and the p value of the burden gene test was 
nearly 0.05 (p=0.55) with frequency categories (MAF<0.001). Considering the functional 
roles of the genes and previous studies, the most likely candidate genes were SCN1A, 
PRKAG2, RYR2, CFTR, and NOS1 (Figure 4, Table 5), and the mutation information for 
the selected top 5 genes was illustrated in Figure 5 and listed in Supplementary Table 
S12.
External data validation
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To verify the candidate pathogenic genes that we screened, we selected the UK Biobank 
resource for external data validation. The database was the most recent upload of the total 
exome sequencing data from 49,960 participator [20]. We searched for mutations in our 
candidate genes that were associated with arrhythmias in UK Biobank summary statistics 
database. Among these 37 candidate genes (36 genes from the gene-based collapsing 
analysis and RYR2), we obtained information about 33 mutations in 18 genes in this 
database of arrhythmia patients; these genes were SCN1A, PRKAG2, CFTR, NOS1, 
PIK3CB, GAD2, HIP1R, ASPH, CD163, SLC9B1, ROBO1, EPHB4, KCNV2, PPFIA1, 
SYT10, COG4, MMP2 and CSF2RB. In particular, mutations in three genes, PIK3CB, 
GAD2 and HIP1R, were present even in patients with PSVT (Figure 6, Table 6, 
Supplementary Table S13). To explore the certain phenotype which burden gene were 
most correlative, the enrichment analysis showed these three burden genes are most 
significant enriched in PSVT (p=0.000174) from 791 phenotypes category in UK 
Biobank (Figure 6, Table 7, Supplementary Table S14 ). 
Because the disease information of UK Biobank was not specific enough, we chose the 
only known AVNRT genetic sequencing study to further validate our candidate 
pathogenic genes. The study, published in 2018, was carried out in Denmark, and 67 
known arrhythmia target genes were detected in AVNRT cases by next-generation 
sequencing[14]. Among our candidate genes, SCN1A, RYR2 and PRKAG2, there were 11 
mutations in SCN1A and 3 mutations in RYR2 detected in AVNRT patients in the Danish 
study, especially, a mutation in RYR2 (c.4652A>G, p.Asn1551Ser, rs185237690) in our 
present study was also found in one Danish AVNRT case, which supports SCN1A and 
RyR2 gene as candidate pathogenic genes in our study. The detail mutations information 
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shown in Table 8.
Discussion
This is, to our knowledge, the first study with the primary aim of investigating the genetic 
component of AVNRT using a WES approach. In the present study and an external data 
validation, genes such as SCN1A, PRKAG2, RYR2, CFTR, NOS1, PIK3CB, GAD2 and 
HIP1R, responsible for neuronal system/neurotransmitter release or ion channel/cardiac 
conduction, are likely to be candidate genes and pathways for AVNRT. As this is only 
the beginning of the genetic investigation of AVNRT, further genetic functional studies 
are needed.
Recently, an increasing number of clinical reports have suggested that there may be a 
hereditary contribution to AVNRT [5-8]. However, much less is known about the 
hereditary contribution to AVNRT compared with that for Wolff-Parkinson-White 
syndrome[9, 10]. A recent study involving the sequencing of 67 selected genes associated 
with arrhythmia in 298 AVNRT patients found the greatest number of mutations in 
sodium and calcium channels, indicating that AVNRT might be an electrical arrhythmic 
disease with abnormal sodium and calcium handling [14]. Among the reference target 
genes from the present study, many mutations were detected in KCNJ12, RYR3, RYR2, 
ZFHX3, ANK2, AKAP9, GNB3, SYNE2, CACNA1D, CACNA1I, GNB3, MYH6, SCN5A, 
SCN1A, SCN3A, HCN4 and KCNH2. Most of these genes, such as KCNJ12, RYR3, RYR2, 
CACNA1D, CACNA1I, SCN5A, SCN1A, SCN3A, HCN4 and KCNH2, encode ion 
channels, indicating that AVNRT was associated with ion channels. Interestingly, the 
causal gene of Wolff-Parkinson-White syndrome, PRKAG2, was also identified in our 
AVNRT cases.
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The autonomic nervous system is known to play an important role in the triggering and 
termination of AVNRT [21-24]. There are extrinsic and intrinsic components of the 
cardiac autonomic nervous system, and the extrinsic component is divided into 
sympathetic and parasympathetic systems, involving the main neurotransmitters of 
norepinephrine and acetylcholine, respectively [25, 26]. The intrinsic cardiac autonomic 
nervous system of the ganglionated plexi (GP) contains both sympathetic and 
parasympathetic fibers and is connected with a wide range of neurotransmitters [27, 28]. 
The AV node exhibits dense parasympathetic innervation, and changes in the cardiac 
autonomic nervous system could lead to arrhythmias [29]. Usually, sympathetic 
stimulation is used to facilitate the induction of AVNRT [21, 22]. However, the onset of 
AVNRT occurs at times of increased vagal tone, as the vagal tone increases the refractory 
period of the fast pathway, and a premature atrial complex may be conducted antegrade 
via the slow pathway with subsequent retrograde conduction, thus initiating AVNRT [23, 
24]. In our present study, many mutations in genes involved in the neurotransmitter 
release cycle and neuronal system pathways, such as the neurotransmitter release cycle, 
acetylcholine neurotransmitter release cycle, serotonin neurotransmitter release cycle, and 
norepinephrine neurotransmitter release cycle, were present among the top 30 enriched 
pathways, the similar outcomes were also presented in GWAS analysis, indicating that 
neurotransmitter release affects the sympathetic or parasympathetic system and then 
induces AVNRT.
The autonomic nervous system also shows a close relationship with cardiac ionic 
conductance. Vagal nerve endings release acetylcholine, activate the ACh-activated K1 
current (IK, ACh) and inhibit the funny current (If) and the L-type Ca2+ current [30]. In 
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contrast, sympathetic nerve endings release noradrenaline to increase the If and the 
L-type Ca2+ current and induce changes in intracellular Ca2+ handling[31]. In addition, 
many arrhythmias occur due to genetic mutations in ion channels themselves, and the 
mutations will affect the sodium, potassium, and calcium channels responsible for ion 
transport across the myocardial cell membrane. Then, the action potential is altered and 
induces arrhythmias [32-34]. In the present study, the pathways of ion channels and 
cardiac conduction were among the top 30 enriched pathways, and genes such as those 
encoding sodium channels (SCN1A) and potassium channels (KCNV2) were selected as 
candidate genes; in particular, SCN1A is regarded as one of the most likely candidate 
pathogenic genes. Mutations in ion channel genes might affect the conduction of AV 
nodes, and differences in conduction velocity will lead to dual AV node physiology and 
AVNRT.
There were three genes with mutations reported to be associated with arrhythmia among 
the candidate genes in the present study. The first was the PRKAG2 gene, encoding the 
gamma2 regulatory subunit of adenosine monophosphate- activated protein kinase 
(AMPK), which was identified as the pathogenic gene of Wolff-Parkinson-White 
syndrome [9, 10]. PRKAG2 mutations induce the slowing of sodium channel inactivation 
and increase the likelihood of channel activation at more negative potentials [35]. The 
integral of the sodium current (total inward current) is a major determinant of conduction 
velocity, and increases in inward sodium current can speed up this process, resulting in a 
conduction velocity change in the AV node[36]. The second gene was SCN1A, which is 
primarily a neuronal gene. Nav1.1, a product of SCN1A, is present in various regions of 
the heart [37, 38]. SCN1A mutations are found in up to 80% of patients with Dravet 
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syndrome, a type of epilepsy observed in infancy, and sudden unexpected death results in 
38% of all deaths in patients with a childhood onset [39]. Although the mechanism 
remains poorly understood, the sodium channel-dependent cardiac current is increased in 
SCN1A-R1407X knock-in mice [40], and autonomic dysfunctions such as abnormalities 
in heart rate variability (HRV), QT and P wave dispersion are observed in patients with 
Dravet syndrome [41], suggesting that some SCN1A variants might cause sudden death or 
lethal arrhythmia through neurocardiac or solely cardiac mechanisms. The third gene was 
RYR2, encoding cardiac ryanodine receptors (RyR2s), which are large intracellular Ca2+ 
channels that control the release of Ca2+ from the sarcoplasmic reticulum in 
cardiomyocytes[42]. Mutations in RYR2 can increase the probability of channel open 
during diastole, resulting in excess diastolic SR Ca2+ release, and the increased SR Ca2+ 
leak during diastole can increase the frequency of spontaneous Ca2+ sparks, resulting in 
an untimely depolarizing inward current that triggers delayed after depolarizations and 
ventricular arrhythmia or atrial fibrillation [42, 43]. As mutations in these three genes 
have been proven to cause arrhythmia by experimental and clinical data, and were 
verified by the external data of UK Biobank and the genetic study from Denmark, it is 
reasonable for us to assume that the gene mutations identified in the present study could 
also cause AVNRT. 
Among the other two candidate genes, the first was CFTR. It encodes a cAMP-activated 
chloride channel (cystic fibrosis transmembrane conductance regulator, CFTR) and is 
expressed mainly in epithelial cells of the respiratory and digestive tracts; mutations in 
this gene cause cystic fibrosis [44]. Subsequent studies demonstrated that CFTR acts not 
only as an ATP-gated chloride channel but also as a regulator of other ion channels, such 
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as amiloride-sensitive Na+ channels, ATP channels and inward rectifier K+ channels [45- 
47]. Recently, in cardiac CFTR-overexpressing mice, intracardiac electrophysiological 
studies showed marked slowing of conduction parameters, including high-grade AV 
block, with easily inducible non-sustained ventricular tachycardia following isoproterenol 
administration [48]. The second of these genes was NOS1. It encodes neuronal nitric 
oxide synthase (nNOS) and is a major isoform within the brain [49]. nNOS, together with 
its adaptor protein (CAPON), is also found in both intrinsic cardiac vagal neurons and 
postganglionic sympathetic neurons of the stellate ganglia [50, 51]. Moreover, the 
overexpression of nNOS increases acetylcholine release [52], and CAPON 
overexpression in myocytes attenuates the L-type calcium current, slightly increases the 
rapid delayed rectifier current (IKr), and shortens action potentials [53], which causes 
arrhythmia susceptibility. Thus, although the two candidate genes CFTR and NOS1 have 
not been proven to directly cause arrhythmia, all the potential evidence listed above 
shows that these gene mutations can change some characteristics of atrioventricular node 
conduction by affecting the autonomic nervous system/neurotransmitter release or ion 
channels, which can lead to changes in cardiac depolarization, action potentials, cardiac 
conduction velocity, the refractory period, etc., and such changes will lead to dual AV 
node physiology and AVNRT.
 As for the three candidate genes, PIK3CB, GAD2 and HIP1R, were present even in 
patients with PSVT in the UK Biobank resource. However, there were no data showed 
any roles of them in the arrythmia. PIK3CB encodes an isoform of the catalytic subunit of 
phosphoinositide 3-kinase beta (PI3Kβ), recent data showed PI3K signaling activation 
affected currents of multiple ion channels, including calcium and sodium channels, and 
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suppression of PI3K activation displayed a prolonged QT interval [54]. GAD2 is a 
glutamate decarboxylase 2 coding gene, diseases associated with GAD2 include 
autoimmune polyendocrine syndrome and stiff-person syndrome, among its related 
pathways are neurotransmitter release cycle and  database. Diseases associated with 
HIP1R (Huntingtin Interacting Protein 1 Related) include expressive language disorder 
and cataract. At present, there is a lack of data about the three gene mutations in 
arrhythmia or AVNRT, which needs to be confirmed by other large samples genetic 
research or functional verification
Limitations
The major limitation of the current study is the small sample size as AVNRT with low 
prevalence in population. When studying rare variants, larger samples are needed to 
adequately show that certain genes or variants are associated with the disorder. Although 
we identified a few candidate genes, such as SCN1A, PRKAG2, RYR2, CFTR, NOS1, 
PIK3CB, GAD2 and HIP1R, in AVNRT in the present study, the genes were not verified 
experimentally, and further research is needed to explore the potential mechanisms of 
these genes. Since AVNRT is caused by complex molecular mechanisms, a single 
pathway is not sufficient to explain the pathogenesis of this disease. Therefore, further 
experimental research is needed to confirm the current findings. Finally, the controls 
included in the present study did not undergo invasive electrophysiological examination, 
and it is possible that the controls were not completely devoid of AVNRT.
Conclusions
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Our study identified a number of potentially disease-related genes, such as SCN1A, 
PRKAG2, RYR2, CFTR, NOS1, PIK3CB, GAD2 and HIP1R, in the pathways of neuronal 
system/neurotransmitter release cycles or ion channel/cardiac conduction, which require 
further replication in larger cohorts and functional confirmation. Because the anatomic 
substrate in AVNRT remains unclear, our findings may provide insight into the 
molecular basis of AVNRT and provide a new view of AVNRT.
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Figure legends
Figure 1  The number of mutations and cases in referential target genes (A, MAF<0.01; 
B, MAF<0.001).
Figure 2  Manhattan plot (A) and pathway enrichment analysis of KEGG (B) and 
Reactome (C).
Figure 3  The top 30 pathways in Reactome pathway enrichment
Figure 4  Protein-protein interaction network. (A) The interaction network between the 
36 candidate genes in gene-based collapsing analysis and the 64 reference target genes 
with mutations in the present study. (B) The interaction network between the 37 
candidate genes (including RYR2) in gene-based collapsing analysis and the genes 
selected by pathway enrichment analysis in GWAS. (C) The interaction network with the 
genes selected by (A) and (B). 
Figure 5  The mutations in the 5 candidate genes such as SCN1A, PRKAG2, RYR2, 
CFTR and NOS1.
Figure 6  Verification of candidate 37 genes in UK Biobank (A); The three of candidate 
burden genes, PIK3CB, GAD2 and HIP1R,  showed the most significant enrichment in 
PSVT (p=0.000174) among 791 phenotypes in UK Biobank (B).
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Table 1  SNPs in genes from the pathway enrichment analysis according to both 
KEGG and Reactome 
Genes A1 F_A F_U A2 P OR Functions Hgv.c Hgv.p
SEMA6D G 0.414 0.225 T 1.10E-4 2.44 Intron variant c.1646+105G>T .
ROBO2 G 0.207 0.075 C 3.18E-4 3.23 Intron variant c.109+121G>C .
MYL12A C 0.161 0.041 CGT 3.48E-4 4.51 Intron variant c.199+192_199+
193delGT
.
ABLIM2 T 0.177 0.345 C 3.49E-4 0.41 Intron variant c.838-131G>A .
ATP2B2 G 0.000 0.060 A 7.05E-4 0.00 Intron variant c.397+71C>T .
ATP2B2 A 0.110 0.025 G 1.02E-3 4.81 Synonymous variant c.1626C>T p.Ile542Ile
ATP2B2 T 0.110 0.025 C 1.02E-3 4.81 Intron variant c.1659+102G>A .
UNC5B T 0.120 0.027 C 1.05E-3 4.89 Intron variant c.305-277C>T .
NEO1 C 0.342 0.195 T 1.80E-3 2.14 Intron variant c.1511+90T>C .
NEO1 TA 0.348 0.200 T 1.90E-3 2.13 3-prime UTR
variant
c.*52_*53insA .
ATP2B2 T 0.183 0.325 G 2.62E-3 0.47 Intron variant c.1417-186C>A .
NEO1 G 0.342 0.200 A 2.77E-3 2.07 Synonymous variant c.1779A>G p.Lys593Lys
ASPH C 0.518 0.359 A 2.80E-3 1.93 Intron variant c.1108-121T>G .
ABLIM2 A 0.232 0.380 G 3.07E-3 0.49 Intron variant c.915+26C>T .
PLXNB1 A 0.043 0.000 G 3.51E-3 Non-coding 
transcript exon 
variant
n.5120C>T .
DPYSL2 T 0.108 0.028 C 3.56E-3 4.22 Intron variant c.936+251C>T .
PLXNC1 T 0.043 0.000 C 3.65E-3 Intron variant c.1062+161C>T .
CACNA1G CTG
TGT
GTG
TGTT
TGT
G
0.049 0.140 C 4.41E-3 0.32 Intron variant c.5782-165_5782-
164insTGTGTGTG
TGTTTGTG
.
ASPH C 0.488 0.340 G 5.26E-3 1.85 Intron variant c.1346-79C>G .
UNC5B T 0.134 0.050 C 5.31E-3 2.94 Splice region
variant
c.732C>T p.Tyr244Tyr
UNC5B A 0.134 0.050 G 5.31E-3 2.94 Intron variant c.734-173G>A .
UNC5B G 0.134 0.050 A 5.31E-3 2.94 Missense variant c.724A>G p.Ile242Val
UNC5B CTG 0.134 0.050 C 5.31E-3 2.94 Intron variant c.1100-35_1100-
34insTG
.
UNC5B T 0.134 0.050 C 5.31E-3 2.94 Intron variant c.901+33C>T .
ASPH T 0.512 0.365 C 5.67E-3 1.83 Intron variant c.1195-57G>A .
UNC5B A 0.128 0.045 G 6.47E-3 3.12 Intron variant c.80-87G>A .
EPHA2 CAG 0.041 0.000 C 6.82E-3 Intron variant c.86-344_86-
343dupCT
.
RYR3 C 0.073 0.015 G 6.92E-3 5.18 Synonymous variant c.2403G>C p.Leu801Leu
RYR3 G 0.073 0.015 A 6.92E-3 5.18 Intron variant c.3556+34A>G .
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RYR2 A 0.061 0.010 G 7.78E-3 6.43 Intron variant c.13317+48G>A .
RYR3 C 0.370 0.240 G 7.95E-3 1.86 Intron variant c.5861-174C>G .
PLXNA4 CAC
ACA
CAA
ACA
T
0.024 0.095 C 8.05E-3 0.24 Intron variant c.3874+275_3874+2
76insATGTTTGTG
TGT
.
SEMA5A C 0.352 0.223 T 8.65E-3 1.89 Intron variant c.1599+327G>A .
RYR1 G 0.012 0.070 A 8.74E-3 0.17 Intron variant c.11689+68A>G .
SLIT3 G 0.253 0.383 A 9.35E-3 0.55 Intron variant c.1459+4296C>T .
RYR2 G 0.438 0.299 A 9.66E-3 1.82 Intron variant c.9128+133A>G .
FES T 0.037 0.11 C 9.71E-3 0.31 Non coding
transcript
exon variant
n.616T>C .
FES A 0.037 0.11 G 9.71E-3 0.31 Intron variant c.388-212A>G .
Notes: A1, Allele 1 (usually minor); FA, Allele 1 frequency among cases; FU, Allele 1 frequency among controls; hgv.c: human genome 
variation c.DNA; hgv.p: human genome variation protein.
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Table 2  Gene-based pathway enrichment according to Reactome (MAF < 0.01)
Pathways ID
Input 
number
Background 
number
P-Value
Corrected 
P-Value
Genes
Neuronal System R-HSA-112316 8 339 0.004 0.048 ABCC8, PPFIA1, LRFN4,
TSPOAP1, BEGAIN, 
GAD2, SYT10, KCNV2
Neurotransmitter Release 
Cycle
R-HSA-112310 3 50 0.007 0.064 TSPOAP1, PPFIA1, 
GAD2
Acetylcholine 
Neurotransmitter Release 
Cycle
R-HSA-264642 2 16 0.008 0.068 TSPOAP1, PPFIA1
Serotonin Neurotransmitter 
Release Cycle
R-HSA-181429 2 17 0.008 0.072 TSPOAP1, PPFIA1
Norepinephrine 
Neurotransmitter Release 
Cycle
R-HSA-181430 2 17 0.008 0.072 TSPOAP1, PPFIA1
Dopamine Neurotransmitter 
Release Cycle
R-HSA-212676 2 22 0.013 0.096 TSPOAP1, PPFIA1
Glutamate Neurotransmitter 
Release Cycle
R-HSA-210500 2 23 0.014 0.100 TSPOAP1, PPFIA1
Axon guidance R-HSA-422475 9 549 0.023 0.133 EPHB4, LAMC1, MMP2,
DOK4, CSF2RB, SCN1A,
EVL, ROBO1, PIK3CB
Cation-coupled Chloride 
cotransporters
R-HSA-426117 1 7 0.057 0.197 SLC12A4
Interactions of neurexins and 
neuroligins at synapses
R-HSA-6794361 2 57 0.070 0.212 BEGAIN, SYT10
Protein-protein interactions
at synapses
R-HSA-6794362 2 57 0.070 0.212 BEGAIN, SYT10
SALM protein interactions at 
the synapses
R-HSA-8849932 1 21 0.149 0.284 LRFN4
Potassium Channels R-HSA-1296071 2 99 0.169 0.300 ABCC8, KCNV2
Metal ion SLC transporters R-HSA-425410 1 25 0.174 0.304 HEPH
Transmission across Chemical 
Synapses
R-HSA-112315 3 208 0.201 0.329 TSPOAP1, PPFIA1, 
GAD2
Inwardly rectifying K+ 
channels
R-HSA-1296065 1 31 0.209 0.334 ABCC8
Vesicle-mediated transport R-HSA-5653656 6 573 0.251 0.369 AP1G2, CD163, CFTR,
PRKAG2, HIP1R,COG4
Voltage gated Potassium 
channels
R-HSA-1296072 1 43 0.276 0.389 KCNV2
Cardiac conduction R-HSA-5576891 2 141 0.281 0.393 SCN1A, NOS1
Ion homeostasis R-HSA-5578775 1 56 0.342 0.439 NOS1
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Ca2+ pathway R-HSA-4086398 1 61 0.366 0.456 TCF7L1
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Table 3  Gene-based pathway enrichment according to Reactome (MAF < 0.001)
Pathways ID
Input 
number
Background 
number
P-Valu
e
Corrected 
P-Value
Genes
Cardiac conduction R-HSA-5576891 3 141 0.0246 0.177 HIPK2, NOS1, ASPH
Ion homeostasis R-HSA-5578775 2 56 0.026 0.179 NOS1, ASPH
Axon guidance R-HSA-422475 6 549 0.034 0.191 COL4A3, EPHB4, 
PSMB11, COL5A1, 
EVL, ROBO1
Ion channel 
transport
R-HSA-983712 3 211 0.066 0.229 SLC9B1, ATP2C2,
ASPH
SALM protein 
interactions at the 
synapses
R-HSA-8849932 1 21 0.091 0.261 LRFN4
Ion transport by 
P-type ATPases
R-HSA-936837 1 57 0.222 0.379 ATP2C2
Transport of 
inorganic cations/
anions and amino 
acids/oligopeptides
R-HSA-425393 1 100 0.354 0.486 SLC26A4
Neuronal System R-HSA-112316 1 339 0.771 0.800 LRFN4
Vesicle-mediated 
transport
R-HSA-5653656 1 573 0.918 0.9236 CD163
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Table 4  Gene-based burden results for candidate genes
MAF<0.01 MAF<0.001
Gene
OR P value Cases Controls OR P value Cases Controls
CFTR 4.67 4.546E-6 68 51 1.89 2.570E-1 6 4
EVL NA* 4.352E-5 12 0 NA 4.352E-05 12 0
HIP1R NA 3.256E-3 7 0 NA 2.016E-1 2 0
ABCC8 NA 7.539E-3 6 0 NA 8.961E-2 3 0
COG4 9.24 1.629E-2 7 1 NA 8.961E-2 3 0
LAMC1 9.24 1.629E-2 7 1 1.22 6.995E-1 1 1
AP1G2 9.24 1.629E-2 7 1 NA 4.505E-1 1 0
GAD2 NA 1.733E-2 5 0 NA 4.505E-1 1 0
CSF2RB NA 1.733E-2 5 0 NA 2.016E-1 2 0
BEGAIN NA 1.733E-2 5 0 NA 8.961E-2 3 0
SYT10 NA 1.733E-2 5 0 NA 4.505E-1 1 0
LRFN4 NA 1.733E-2 5 0 NA 1.733E-2 5 0
NOS1 1.95 2.000E-2 42 35 1.93 2.337E-2 39 32
SLC12A4 5. 2.433E-2 8 2 3.18 1.489E-1 5 2
ROBO1 5.30 2.433E-2 8 2 9.24 1.628E-2 7 1
SFTPA2 3.26 2.447E-2 12 5 5.01 9.055E-3 11 3
TSPOAP1 3.99 3.123E-2 9 3 1.66 3.9110E-1 4 3
KCNV2 7.82 3.324E-2 6 1 2.48 4.257E-1 2 1
PIK3CB 7.82 3.324E-2 6 1 2.48 4.257E-1 2 1
CD163 NA 3.955E-2 4 0 NA 3.955E-2 4 0
PRKAG2 NA 3.955E-2 4 0 NA 4.505E-1 1 0
DOK4 NA 3.955E-2 4 0 NA 2.016E-1 2 0
HEPH NA 3.955E-2 4 0 NA 2.016E-1 2 0
SCN1A NA 3.955E-2 4 0 NA 8.961E-2 3 0
PPFIA1 NA 3.955E-2 4 0 NA 8.961E-2 3 0
EPHB4 4.57 4.592E-2 7 2 7.82 3.324E-2 6 1
MMP2 4.57 4.592E-2 7 2 5.08 1.284E-1 4 1
TCF3 4.57 4.592E-2 7 2 3.76 2.398E-1 3 1
COL5A1 3.50 5.570E-2 8 3 4.57 4.592E-2 7 2
ATP2C2 2.59 1.046E-1 8 4 7.82 3.324E-2 6 1
SLC26A4 2.55 1.606E-1 6 3 NA 3.955E-2 4 0
ASPH 2.55 1.606E-1 6 3 NA 3.955E-2 4 0
PSMB11 2.24 1.673E-1 7 4 NA 3.955E-2 4 0
RYR2 1.60 2.433E-1 10 8 3.50 5.570E-2 8 3
COL4A3 1.89 2.570E-1 6 4 NA 1.733E-2 5 0
HIPK2 0.94 6.424E-1 7 9 NA 1.733E-2 5 0
SLC9B1 1.00E0 82 100 2.93 3.021E-2 77 84
Note：* NA, not available as the number of cases or controls is zero; MAF, minor allele frequency.
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Table 5  PPI network combined scores
Genes
Number of nodes 
in group 1
Total scores Mean scores
Number of nodes 
in group 2
Total scores Mean scores
Combined mean 
total scores
Combined mean 
number of nodes
RYR2 37 23.226 0.628 10 6.533 0.653 14.880 23.5
NOS1 12 9.121 0.760 5 4.469 0.894 6.795 8.5
SCN1A 18 10.844 0.602 3 1.297 0.432 6.071 10.5
CFTR 8 5.596 0.700 5 3.750 0.75 4.673 6.5
EPHB4 4 2.463 0.616 11 6.508 0.592 4.483 7.5
PRKAG2 14 7.370 0.526 2 1.299 0.650 4.335 8
ROBO1 3 1.958 0.653 10 6.524 0.652 4.241 6.5
ASPH 4 3.105 0.776 3 2.897 0.966 3.001 3.5
MMP2 4 2.741 0.685 4 2.589 0.647 2.665 4
ABCC8 8 4.278 0.535 1 0.496 0.496 2.387 4.5
ATP2C2 4 2.077 0.519 5 2.687 0.537 2.382 4.5
COL5A1 3 2.28 0.760 3 2.280 0.760 2.280 3
CSF2RB 2 1.819 0.910 3 2.340 0.780 2.080 2.5
PIK3CB 3 1.977 0.659 2 1.361 0.681 1.669 2.5
COL4A3 3 1.782 0.594 2 1.356 0.678 1.569 2.5
HIPK2 3 2.433 0.811 1 0.625 0.625 1.529 2
SFTPA2 2 1.841 0.921 1 0.917 0.917 1.379 1.5
HIP1R 2 1.800 0.900 1 0.900 0.900 1.350 1.5
EVL 1 0.925 0.925 2 1.503 0.752 1.214 1.5
SLC26A4 2 1.143 0.572 2 1.186 0.593 1.165 2
PPFIA1 1 0.933 0.933 1 0.933 0.933 0.933 1
GAD2 2 0.929 0.465 2 0.929 0.465 0.929 2
PSMB11 1 0.905 0.905 1 0.905 0.905 0.905 1
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TCF7L1 1 0.625 0.625 1 0.625 0.625 0.625 1
LAMC1 1 0.553 0.553 1 0.553 0.553 0.553 1
KCNV2 1 0.926 0.926 NA NA NA 0.463 0.5
COG4 1 0.902 0.902 NA NA NA 0.451 0.5
SLC12A4 1 0.591 0.591 NA NA NA 0.296 0.5
SYT10 1 0.400 0.400 NA NA NA 0.200 0.5
Notes: group1 means the PPI network was constructed with 36 candidate genes from gene-based collapsing analysis and 64 referential target genes with mutations in the present study; group2 means the PPI network was constructed 
with 37 candidate genes (including RYR2) from gene-based collapsing analysis and 20 selected genes in the top-30 enrichment pathways with both KEGG and Reactome databases in GWAS analysis; NA, not available.
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Table 6  The external data validation of candidate genes by the UK Biobank resource
Genes Start position End position
Number of
Rare variants
MAC-cases MAC-controls Cases Controls P-value
Phenotype 
code
Phenotype name
ASPH 8:61503374:G:C 8:61651126:T:C 220 89.00 1663.043487 2570 42728 4.035E-2 427.00 Cardiac dysrhythmias
CD163 12:7479895:T:C 12:7502526:T:C 69 4 150.0004211 95 9405 3.605E-2 426.91 Cardiac pacemaker in situ
CD163 12:7479895:T:C 12:7502526:T:C 79 5 171.00 108 10692 9.246E-3 426.90 Cardiac pacemaker/device in situ
CFTR 7:117480105:C:T 7:117592658:G:A 197 14.00 932.09 95 9405 7.580E-3 426.91 Cardiac pacemaker in situ
COG4 16:70481032:T:C 16:70512433:C:T 62 4 151 93 9207 4.767E-4 427.50 Arrhythmia (cardiac) NOS
CSF2RB 22:36922267:C:A 22:36938476:G:A 92 4 234.00 108 10692 8.011E-3 426.9 Cardiac pacemaker/device in situ
CSF2RB 22:36922267:C:A 22:36938476:G:A 84 4 202.00 95 9405 5.619E-3 426.91 Cardiac pacemaker in situ
CSF2RB 22:36922267:C:A 22:36938476:G:A 79 5 219 104 10296 2.413E-2 427.40 Cardiac arrest and ventricular fibrillation
EPHB4 7:100803517:A:G 7:100826991:C:T 107 10 487.00 116 11484 1.433E-2 425.00 Cardiomyopathy
EPHB4 7:100805215:C:T 7:100826991:C:T 81 5 181.01 78 7722 1.302E-2 427.12 Paroxysmal ventricular tachycardia
GAD2 10:26216843:G:A 10:26245919:A:G 76 17 1590.00 276 27324 1.285E-2 427.11 Paroxysmal supraventricular tachycardia
GAD2 10:26216843:G:A 10:26245919:A:G 85 19 2030.00 354 35046 2.535E-2 427.10 Paroxysmal tachycardia, unspecified
HIP1R 12:122834989:T:C 12:122860524:G:A 144 11 472.00 108 10692 4.155E-3 426.90 Cardiac pacemaker/device in situ
HIP1R 12:122834978:A:C 12:122861041:T:C 291 24.00 1507.01 354 35046 1.837E-2 427.10 Paroxysmal tachycardia, unspecified
HIP1R 12:122834989:T:C 12:122860524:G:A 126 8 355.00 78 7722 2.860E-2 427.12 Paroxysmal ventricular tachycardia
HIP1R 12:122834989:T:C 12:122860524:G:A 249 17.00 1185.01 276 27324 2.887E-2 427.11 Paroxysmal supraventricular tachycardia
HIP1R 12:122834989:T:C 12:122860524:G:A 134 11 418.00 95 9405 1.179E-3 426.91 Cardiac pacemaker in situ
KCNV2 9:2717744:D:4 9:2729710:D:5 88 5.00 199.00 87 8613 4.110E-3 427.42 Cardiac arrest
KCNV2 9:2717744:D:4 9:2729710:D:5 91 5.00 218.00 104 10296 4879553E-3 427.40 Cardiac arrest and ventricular fibrillation
MMP2 16:55479557:C:A 16:55505425:G:A 53 2 91.00 78 7722 4.910E-2 427.12 Paroxysmal ventricular tachycardia
NOS1 12:117218074:T:C 12:117278099:C:G 272 143.00 3398.00 1468 42760 1.183E-2 427.20 Atrial fibrillation and flutter
PIK3CB 3:138655414:G:A 3:138759288:G:A 95 5 213.00 276 27324 3.915E-2 427.11 Paroxysmal supraventricular tachycardia
PPFIA1 11:70272251:C:G 11:70382137:C:G 73 3 137.00 78 7722 4.004E-2 427.12 Paroxysmal ventricular tachycardia
PRKAG2 7:151557224:G:A 7:151675419:C:T 38 2 51 78 7722 1.452E-2 427.12 Paroxysmal ventricular tachycardia
PRKAG2 7:151557224:G:A 7:151595452:C:T 36 4 52.00 87 8613 1.868E-4 427.42 Cardiac arrest
PRKAG2 7:151557224:G:A 7:151595452:C:T 41 4 62.00 104 10296 2.122E-4 427.40 Cardiac arrest and ventricular fibrillation
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ROBO1 3:78600114:T:A 3:79018406:C:T 344 56.00 1702.02 1468 42760 2.524E-3 427.20 Atrial fibrillation and flutter
ROBO1 3:78600114:T:A 3:79018406:C:T 350 92.01 1700.02 2570 42728 1.813E-2 427.00 Cardiac dysrhythmias
ROBO1 3:78600114:T:A 3:78598929:T:C 118 8.00 344.01 93 9207 3.817E-2 427.50 Arrhythmia (cardiac) NOS
SCN1A 2:165991287:T:G 2:166041470:C:A 85 6 274.02 104 10296 3.253E-4 427.40 Cardiac arrest and ventricular fibrillation
SCN1A 2:165991287:T:G 2:166041470:C:A 69 6 225.02 87 8613 1.139E-4 427.42 Cardiac arrest
SLC9B1 4:102901162:A:T 4:102991714:T:C 47 17 736.01 104 10296 2.837E-2 427.40 Cardiac arrest and ventricular fibrillation
SYT10 12:33376837:G:A 12:33439521:A:G 46 3 97.00 116 11484 1.042E-2 425.00 Cardiomyopathy
Note: MAC: Minor allele counts.
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Table 7  Candidate Genes Enrichment Analysis for Phenotype Category in UK Biobank (p<0.05)
Phenotype category name Enrichment P value -Log10(P value) Category name Phenotype code
Paroxysmal supraventricular tachycardia 0.000174146 3.759 circulatory system 427.11
Paroxysmal tachycardia, unspecified 0.009124029 2.040 circulatory system 427.1
Aneurysm and dissection of heart 0.01165878 1.933 circulatory system 411.41
Other hypertrophic and atrophic conditions of skin 0.007023506 2.153 dermatologic 701
Nephritis; nephrosis; renal sclerosis 0.010817149 1.966 genitourinary 580
Intestinal infection due to C. difficile 0.0137383 1.862 infectious diseases 008.52
Anaphylactic shock NOS 0.014210121 1.847 injuries & poisonings 946
Opiates and related narcotics causing adverse effects in therapeutic use 0.01073407 1.969 injuries & poisonings 965.1
Bacterial pneumonia 0.008187189 2.087 respiratory 480.1
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